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Abstract
Background: Pulmonary hypertension leads to right ventricular heart failure and ultimately to cardiac cachexia.
Cardiac cachexia induces skeletal muscles atrophy and contractile dysfunction. MAFbx and MuRF1 are two key
proteins that have been implicated in chronic muscle atrophy of several wasting states.
Methods: Monocrotaline (MCT) was injected over eight weeks into mice to establish pulmonary hypertension as a
murine model for cardiac cachexia. The effects on skeletal muscle atrophy, myofiber force, and selected muscle
proteins were evaluated in wild-type (WT), MuRF1, and MuRF2-KO mice by determining muscle weights, in vitro
muscle force and enzyme activities in soleus and tibialis anterior (TA) muscle.
Results: In WT, MCT treatment induced wasting of soleus and TA mass, loss of myofiber force, and depletion of
citrate synthase (CS), creatine kinase (CK), and malate dehydrogenase (MDH) (all key metabolic enzymes). This
suggests that the murine MCT model is useful to mimic peripheral myopathies as found in human cardiac cachexia.
In MuRF1 and MuRF2-KO mice, soleus and TA muscles were protected from atrophy, contractile dysfunction, while
metabolic enzymes were not lowered in MuRF1 or MuRF2-KO mice. Furthermore, MuRF2 expression was lower in
MuRF1KO mice when compared to C57BL/6 mice.
Conclusions: In addition to MuRF1, inactivation of MuRF2 also provides a potent protection from peripheral
myopathy in cardiac cachexia. The protection of metabolic enzymes in both MuRF1KO and MuRF2KO mice as well
as the dependence of MuRF2 expression on MuRF1 suggests intimate relationships between MuRF1 and MuRF2
during muscle atrophy signaling.
Keywords: Cardiac cachexia, Pulmonary hypertension, Muscle atrophy, Myofibrillar proteins, MuRF1 and MuRF2,
Muscle energy metabolism
Background
Skeletal muscle mass adapts rapidly to activity by either
activating hypertrophic or atrophic pathways. Muscle
atrophy occurs as a result of changes in the balance
between anabolic and catabolic processes and in many clin-
ical conditions, like chronic heart failure [1–3], limb
immobilization [4, 5], mechanical ventilation [6, 7], sepsis
[8], diabetes [9], and advanced aging [10] skeletal muscle
mass is lost, leading to muscle weakness, inactivity and
increased mortality. The activation of both the autophagic/
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lysosomal proteolysis and the ubiquitin proteasome system
(UPS) are recognized to play important roles in the protein
breakdown. Especially the UPS system and relevant ubiqui-
tin E3-ligases are discussed as potential targets to modulate
skeletal muscle atrophy. Performing transcript profiling in
several atrophy models identified MuRF1 and MAFbx as
ubiquitin E3 ligases only expressed in heart and skeletal
muscle [11]. MuRF1 belongs to a family of MuRF proteins
consisting of MuRF1, MuRF2 and MuRF3 [12]. MuRF1
knockout animal’s exhibit resistance towards the develop-
ment of skeletal muscle atrophy [11, 13] and when sub-
jected to chronic pressure overload the animals developed
massive cardiac hypertrophy [14]. MuRF2 seems to be in-
volved in sarcomere formation [15] and intracellular signal-
ing in cardiomyocytes by decreasing serum response
transcription factor (SRF) during mechanical inactivity [16].
Furthermore, MuRF2 in mononuclear cells attenuates
LPS-induced macrophage activation by inhibiting the
generation of inflammatory cytokines [17]. MuRF3
binds to microtubules helping to develop a network
resistant to depolarization [18], plays a role in myosin
protein quality control [19] and protects against dia-
betic cardiomyopathy [20].
Studies analyzing the myocardium of knockout
(KO) animals suggest that MuRF1 and MuRF2 play a
redundant role in regulating developmental physio-
logic hypertrophy [21]. Synergistic cooperation be-
tween MuRF1 and MuRF2 is further supported by the
observation that MuRF1/MuRF2 double KO animals
present a fulminant cardiac phenotype (74% early
postnatal lethality with acute heart failure), whereas
single knockout animals are healthy with normal life
span and myocardial functionality [22]. This cooper-
ation among MuRFs and with other atrogenes like
MAFbx was also documented in MuRF1 KO mice
undergoing denervation [23] or aging [24], where a
significant upregulation of MAFbx was observed when
compared to wild-type animals. A molecular explan-
ation for the cooperation between MuRF1 and
MuRF2 may be their shared recognition of 35 or
more protein targets [22]. These cooperative effects of
MuRF1 and MuRF2 are mainly shown in the myocar-
dium but less data are available for skeletal muscle
remodeling in experimental heart failure. Therefore,
the aim of the present study was to induce heart fail-
ure in MuRF1 and MuRF2 knockout mice and com-
pare the development of muscle atrophy and
dysfunction to wild-type littermates.
Methods and materials
Animals and study design
The mice used in this study are all on a clean C57/BL6
background. Details on the gene inactivation of MuRF1
and MuRF2 are described in Witt et al. [22]. To induce
cardiac cachexia monocrotaline (MCT) was subcutane-
ously injected weekly at a concentration of 600 mg/kg
into either C57/BL6 (WT, n = 9), MuRF-1 (n = 11), and
MuRF-2 (n = 9) knockout animals for 8 weeks. Control
animals of each group received the same volume of sa-
line (C57/Bl6 n = 12; MuRF-1−/− n = 11; MuRF-2−/− n =
11). Body weight was recorded every week for each ani-
mal. Animals were exposed to identical conditions under
a 12:12 h light/dark cycle with food and water provided
ad libitum. Mice were sacrificed following deep
anesthetization with i.p. administration of fentanyl (0.05
mg/kg), medetomidine (0.5 mg/kg), midazolam (5 mg/
kg), and ketamine (100 mg/kg). At sacrifice, the heart
and lungs were dissected, cleaned, blotted dry, and
weighed, with the heart fixed in 4% PBS-buffered forma-
lin. The left tibialis anterior (TA) and soleus (SO)
muscle were dissected, weighed, and fixed in 4% PBS-
buffered formalin, while the remaining muscle portions
were immediately frozen in liquid N2 for molecular ana-
lysis. Muscle wet weights were normalized to tibia
length, which allowed a fair comparison of relative
changes in muscle mass between all groups due to
differences in body weight.
All experiments and procedures were approved by the
local Animal Research Council, University of Leipzig
and the Landesbehörde Sachsen (TVV 40/16).
Contractile function
The SO of the right leg was dissected to allow in vitro
contractile function to be assessed using a length-
controlled lever system (301B, Aurora Scientific Inc.,
Aurora, Canada), as previously described [25, 26].
Briefly, a muscle bundle was mounted vertically in a
buffer-filled organ bath (~ 22 °C), set at optimal length,
and after 15 min was stimulated over a force-frequency
protocol between 1 and 300 Hz (600 mA; 500 ms train
duration; 0.25 ms pulse width). Force (N) was normal-
ized to muscle cross-sectional area (CSA; cm2) by divid-
ing muscle mass (g) by the product of Lo (cm) and
estimated muscle density (1.06), which allowed specific
force in N/cm2 to be calculated.
Tissue analyses
Histology
The heart (medial section), the SO, and TA muscle were
embedded in paraffin; 3 μm sections were obtained,
which where mounted on slides and stained with
hematoxylin and eosin. Sections were than captured as
images on a computer connected to a microscope and
subsequently evaluated using Analysis software (Analysis
3.0, Olympus Soft Imaging Solutions GmbH, Münster,
Germany). As recently described [25], RV wall thickness
(in μm) was determined from the mean of 10 individual
measurements distributed along the free ventricular wall,
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while mean fibre CSA (in μm2) of the soleus and TA
was evaluated after assessment of approximately 300–
500 fibers per animal.
Western blot analysis
For western blot analyses, frozen TA was homogenized
in Relax buffer (90 mmol/L HEPES, 126 mmol/L potas-
sium chloride, 36 mmol/L sodium chloride, 1 mmol/L
magnesium chloride, 50 mmol/L EGTA, 8 mmol/L ATP,
10 mmol/L creatine phosphate, pH 7.4) containing a
protease inhibitor mix (Inhibitor mix M, Serva, Heidel-
berg, Germany), sonicated, and centrifuged at 16,000xg
for 5 min. Protein concentration of the supernatant was
determined (BCA assay, Pierce, Bonn, Germany) and ali-
quots (5–20 μg) were separated by SDS-polyacrylamide
gel electrophoresis. Proteins were transferred to a polyvi-
nylidene fluoride membrane (PVDF) and incubated
overnight at 4 °C with the following primary antibodies:
MuRF1 (1/1000, Abcam, Cambridge, UK), MuRF2 (1:
1.600, Myomedix GmbH, Neckargemünd, Germany).
Membranes were subsequently incubated with a horse-
radish peroxidase-conjugated secondary antibody and
specific bands visualized by enzymatic chemilumines-
cence (Super Signal West Pico, Thermo Fisher Scientific
Inc., Bonn, Germany) and densitometry quantified using
a 1D scan software package (Scanalytics Inc., Rockville,
USA). Blots were then normalized to the loading control
GAPDH (1/30000; HyTest Ltd, Turku, Finland). All data
are presented as fold change relative to control.
Enzyme activity measurements
TA was homogenized in Relax buffer and aliquots were
used for enzyme activity measurements. Enzyme activ-
ities for citrate synthase (CS, EC 2.3.3.1), creatine kinase
(EC 2.7.3.2), and malate dehydrogenase (EC 1.1.1.37)
were measured spectrophotometrically as described in
detail [27, 28]. Enzyme activity data are presented as the
fold change vs. control.
Statistical analyses
Data are presented as mean ± SEM. Unpaired t test was
used to compare groups, while two-way repeated mea-
sures ANOVA followed by Bonferroni post hoc test was
used to assess contractile function (GraphPad Prism).
Significance was accepted as p < 0.05.
Results
Comparison of cachexia response to MCT stress in WT,
MuRF1, MuRF2 KO mice
Weekly injections of MCT into WT mice are suitable to
establish a chronic cardiac cachexia condition as previ-
ously described (see [25, 29]): MCT treatment of WT
animals for 8 weeks resulted in increased lung weight
(Fig. 1a), increased heart weight (Fig. 1b), and right
ventricular hypertrophy (Fig. 1c; p for all groups < 0.01).
Cachexia was evident after 8 weeks in WT mice with
regards to their whole body weights: While control
animals increased body weights by 15%, MCT mice
developed a 9% reduction in body weights during
the 8-week study period (Fig. 1d, p = 0.001). Lung
and heart tissues in MuRF1 and MuRF2 KO mice
responded to MCT injection similar as WT mice,
and total lung and heart eights, as well as RV thick-
ness were augmented at week 8 (Fig. 1a–c). How-
ever, the effects on body weights differed in the WT,
MuRF1, and MuRF2 KO groups: MuRF1−/− animals
lost 7% of body weight (p = 0.09 MCT vs. NaCl
treatment), whereas MuRF2−/− lost 4% (no statistical
significance when compared to NaCl-treated coun-
terparts; Fig. 1d).
TA and SO muscles differ in their response to MCT in WT,
MuRF1 and MuRF2 KO mice
Quantifying muscle weight of the tibialis anterior (Fig. 2a)
and soleus muscle (Fig. 2b) in wild-type and in MuRF1KO
and MuRF2KO mice, a significant higher muscle weight
was evident in MuRF1KO and MuRF2KO mice when
compared to C57BL/6 animals. In accordance with our
recent study [25], the whole body weight losses of WT
mice underlies a progressing muscle atrophy during the
eight week MCT treatment. Different degrees of muscle
weight losses are present in TA and SO: while TA and SO
lost about 10% total wet weights (Fig. 2c, d) (TA 10% loss,
soleus 11% loss), the fiber cross-sectional area (CSA) were
even markedly lower (TA 32% lowered CSA; SO 15% low-
ered CSA) (Fig. 2e, f). In contrast, inactivation of either
MuRF1 or MuRF2 protected mice from MCT induced at-
rophy features both with regards to muscle wet weight
(Fig. 2c, d) and fiber CSA (Fig. 2e, f). No significant differ-
ences between the NaCl and MCT groups were observed
in any of the MuRF1KO and MuRF2KO SO or TA muscle
measures.
MCT-induced SO muscle force depletion is prevented by
MuRF1 or MuRF2 inactivation
Next, we compared contractile properties of isolated
muscle bundles from MCT-stressed and control mice
by our force-frequency protocol (see “Methods” sec-
tion above). Consistent with our earlier results [25],
treatment of C57Bl/6 mice with MCT for 8 weeks
resulted in a 16% loss of absolute SO myofiber force
(Fig. 3a; p < 0.01). However, no change was apparent
after normalization to muscle mass in terms of spe-
cific myofiber force (Fig. 3b).
In vitro comparisons of SO muscle contractility
between non-MCT-treated C57BL/6, MuRF1KO and
MuRF2KO mice revealed a significant higher absolute
force in both knockout strains (C57BL/6 24.5 ± 0.6 g;
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MuRF1KO 27.6 ± 1.1 g p < 0.05 vs. C57BL/6;
MuRF2KO 28.2 ± 1.4 g p < 0.05 vs. C57BL6). How-
ever, after normalization to muscle mass, specific
force was not different the different strains (C57BL/6
27.7 ± 0.5 N/cm2; MuRF1KO 27.8 ± 0.9 N/cm2;
MuRF2KO 28.5 ± 0.6 N/cm2). Intriguingly, MCT
treatment for 8 weeks in did not have an impact on
absolute or specific muscle forces in both MuRF1KO
(Fig. 3c, d) and in MuRF2KO mice (Fig. 3e, f).
Impact of MCT treatment on atrophy-associated protein
expression
Next, during MCT stress we assessed the protein expres-
sion of MafBx and MuRF1 (two key atrogin factors). We
included MuRF2 as its gene inactivation also protect
from atrophy and wasting (see Figs. 1, 2, and 3).
The treatment of C57BL/6 mice with MCT for a
period of 8 weeks resulted in a significant increased
expression of MafBx (Fig. 4a), MuRF1 (Fig. 4b), and
MuRF2 (Fig. 4c). This MCT-induced upregulation of
these atrogenes was not seen in MuRF1 and MuRF2KO
animals. Interestingly, even a downregulation of MafBx
was noted in MuRF2KO animals when treated with
MCT (Fig. 4a). Finally, we tested if the expression of
MuRF1 influences the expression of MuRF2. For this,
we determined the expression of MuRF2 in TA muscle
from MuRF1KO animals. Intriguingly, gene inactivation
of MuRF1 also markedly lowered the expression of
MuRF2 (see Fig. 4d for comparison of MuRF2 levels in
TA of MuRF1 KO and C57BL/6 WT animals).
Depletion of energy delivering enzymes by MCT
treatment and rescue from this by MuRF1 and 2 gene
inactivation
In our recent study [25] on MCT induced cardiac cach-
exia, we noted a depletion of enzymatic activities that
generate ATP in myocytes. We therefore determined
again the activity of these enzymes under MCT-stress
but included also muscle extracts from MuRF1 and 2
KO mice. Consistent with our recent study [25],
Fig. 1 Physical characteristics of NaCl- or monocrotaline (MCT)-treated C57BL/6 wild-type animals or MuRF1 and MuRF2 knockout animals. When
compared to the NaCl-treated animals, the administration of MCT to the animals had significant effects on final body weight (a), lung weight (b),
heart weight (c), and the thickness of the right ventricle (d) independent of the phenotype. Data are presented as mean ± SEM
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treatment of C57BL6 animals with MCT resulted in
reduced enzyme activities for CS (Fig. 5a), creatine kin-
ase (Fig. 5b), and MDH (Fig. 5c). In contrast, MuRF1−/−
animals showed an upregulation of these enzymes that
are connected to mitochondrial energy metabolism in
muscle. In MuRF2−/− animals, MCT did not alter
enzyme activities of CS, CK, and MDH in TA muscles
(Fig. 5a–c).
Discussion
Skeletal muscle atrophy occurs frequently in a variety of
diseases, including tumor, chronic heart failure, diabetes,
sepsis, and mechanical ventilation, contributing to a re-
duced muscle function and reduced quality of life. The
understanding of molecular mechanisms and the rele-
vance of specific proteins for the development of muscle
dysfunction/muscle atrophy is essential for developing
effective treatment strategies. In the present study we in-
vestigated in mouse models the roles of MuRF1 and
MuRF2 for the development of muscle atrophy and
muscle dysfunction in a right ventricular heart failure
setting that mimics human heart failure during chronic
pulmonary hypertension. The results of the present
study can be summarized as follows: (1) the develop-
ment of heart failure is associated with muscle atrophy
and muscle dysfunction (loss of absolute force). This is
not observed in MuRF1KO and MuRF2KO− animals. (2)
Muscle mass is already higher in the MuRF1KO and
MuRF2KO animals when compared to WT mice inde-
pendent of heart failure induction, (3) muscle atrophy
induced by MCT goes along with the activation of
MuRF1, MuRF2, and MAFbx, and a downregulation of
enzymes involved in mitochondrial energy production
and energy transfer, (4) the expression of MuRF1 influ-
ences also the expression of MuRF2.
Importance of MuRF1 and MuRF2 for muscle atrophy in
cardiac cachexia
Cardiac cachexia and the development of heart failure
are often associated with skeletal muscle atrophy, being
Fig. 2 Skeletal muscle wet weight (normalized to tibia length) and cross-sectional area for soleus and tibialis anterior (TA). Muscle wet weight for
the TA (a) and soleus (b) is significantly increased in both knockout animals (MuRF1KO and MuRF2KO) when compared to C57BL/6 mice.
Administration of monocrotaline (MCT) to the animals resulted in a reduced muscle wet weight of the TA (c) and soleus muscle (d) in the C57BL/
6 animals, whereas MCT had no effect on muscle wet weight in the MuRF1KO and MuRF2KO animals (c, d). In addition, also the cross-sectional
area (CSA) of TA (e) and soleus (f) was reduced in C57BL/6 whereas this reduction was not seen in MuRF1KO and MuRF2KO mice. Data are
presented as mean ± SEM
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an independent prognostic marker for survival [30–33].
Therefore, understanding the molecular pathways acti-
vated and resulting in muscle atrophy are potential tar-
gets to develop specific treatment strategies to fight
muscle loss and modulate morbidity and mortality. Dif-
ferential transcriptional profiling has identified MuRF1
and MAFBx as markers for muscle atrophy [11, 34] and
their genetic deletion resulted in muscle sparing
following hind-limb unloading [35], denervation [11], or
glucocorticoid treatment [36]. In the present study, we
used monocrotaline to induce muscle atrophy. The
application of monocrotaline to mice resulted in the de-
velopment of pulmonary hypertension and right ven-
tricular hypertrophy, evident by the increased thickness
of the right ventricular wall. Inducing cardiac cachexia
in C57Bl6 mice resulted in muscle atrophy as described
in the current literature [25, 29, 37]. Giving monocrota-
line to either MuRF1 or MuRF2 knockout animals this
induction of muscle atrophy was not evident. This
clearly shows for the first time that not only MuRF1 is
essential for the induction of muscle atrophy, but also
the expression of MuRF2 is critical for the development
Fig. 3 In vitro skeletal muscle function of the soleus muscle determined in C57BL/6 (a, b), MuRF1KO (c, d), and MuRF2KO (e, f) animals. Muscle
force is shown as absolute force (a, c, e) and as specific force (b, d, f). Monocrotaline significantly impaired absolute muscle force only in C57BL6
animals (a) but not in MuRF1KO (c) and MuRF2KO mice (e). Monocrotaline had no effect on muscle specific force. Data are presented as mean ±
SEM. Control animals are depicted in black squares and solid line whereas MCT-treated animals are shown in triangles and dotted lines
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of muscle atrophy. Furthermore there seems to exist a
cooperation or a cross-talk between MuRF1 and MuRF2
since the deletion of MuRF1 resulted, without induction
of muscle atrophy, in a lower expression of MuRF2. This
is in line with a recent observation by Silva et al. describ-
ing that MuRF1 directed siRNAs also knock-down ex-
pression of MuRF2 mRNA expression in cultured
myotubes [38]. These findings point to an intimate con-
nectivity between both MuRF1 and MuRF2.
The relevance of MuRF1 and MuRF2 for modulat-
ing muscle mass and muscle function is furthermore
supported by our observation that the absolute
muscle force is significantly higher in the MuRF1 and
MuRF2 knockout animals. The molecular pathways
controlled by MuRF1/2 leading to muscle atrophy
therefore warrant more studies with regard to coop-
erativity and their signaling interrelationships: While
MuRF1 ablation has been extensively studied in the
context of myofibrillar protein degradation, MuRF2
was implicated in nuclear strength-regulated
transcription [16]. Our data here point to joint roles
in energy metabolism as another important pathway
affected by both MuRF1 and MuRF2. Interestingly,
the MCT-induced reduction of enzymes involved in
mitochondrial energy production is different in
MuRF1 and MuRF2 KO animals. This may point to-
wards an interesting divergence in the mechanisms
underlying the actions of MuRF1 and MuRF2 in this
cachexia model for inducing muscle dysfunction. The
different role with respect to enzymes involved in en-
ergy production is supported by the observation by
Willis and colleagues [39] who observed in MuRF1
transgenic animals (specific overexpression in the
heart) a significantly reduced CK activity. Applying a
yeast two hybrid screen to identify specific MuRF1
and MuRF2 targets Witt and colleagues [40] reported
that mainly myofibrillar proteins are targets for both
MuRF1 and MuRF2 whereas the situation for en-
zymes involved in energy production is less clear.
Nevertheless, more research is necessary to clarify the
Fig. 4 Protein expression of atrophy related proteins in the TA muscle C57BL/6, MuRF1KO, and MuRF2KO mice. MAFbx (a), MuRF1 (b), and MuRF2
(c) protein expression was quantified in NaCl- or monocrotaline-treated animals. To test for cooperativity between MuRF1 and MuRF2, MuRF2
expression was assessed also in C57BL6 MuRF1KO mice (d). Data are presented as mean ± SEM and representative blots are depicted. In the
representative blot KO = MuRF-1 KO mice; WT = C57BL/6 mice
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Fig. 5 Enzymatic activity of citrate synthase (a), creatine kinase (b), and malate dehydrogenase (c) in the TA muscle C57BL/6, MuRF1KO, and
MuRF2KO mice treated either with NaCl or monocrotaline. Data are presented as mean ± SEM
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exact role of MuRF1 and MuRF2 and their interaction
in inducing muscle atrophy and muscle dysfunction.
Clinical considerations
The results discussed here were obtained using well
established and previously extensively characterized KO
models for MuRF1 and 2 [22, 40]. The results of the
present investigation suggest that modulating MuRF1
and/or MuRF2 expression may be an attractive approach
in the future to influence the development of muscle at-
rophy in cardiac cachexia. Unfortunately, it will be im-
portant not to completely inhibit the activity of both
MuRF1 and MuRF2, because MuRF1/MuRF2 double
knockout animals display a severe phenotype including
severe cardiac hypertrophy massively reduced left ven-
tricular ejection fraction and signs of heart failure [21,
22]. A recently developed and tested MuRF1/2 inhibitor
from our group prevented the development of muscle
atrophy and exhibited no severe side effects and was well
tolerated. One possible explanation for its “side-effect”-
free action is probably due to the fact that the inhibitor
was screened to inhibit the interaction of MuRF1 with
its target proteins but leaving its activity intact. More
emphasis seems to be warranted for further drug devel-
opment or chemical modulation of the described small
molecule and for testing in other models of muscle
wasting.
Conclusion
In the present study, we show for the first time that in
addition to MuRF1, inactivation of MuRF2 also provides
a potent protection from peripheral myopathy and skel-
etal muscle dysfunction in cardiac cachexia. The protec-
tion of metabolic enzymes in both MuRF1KO and
MuRF2KO mice as well as the dependence of MuRF2
expression on MuRF1 suggests intimate relationships be-
tween MuRF1 and MuRF2 during muscle atrophy sig-
naling. These results also suggest that the development
of a MuRF inhibitor to prevent the development of
muscle atrophy should target MuRF1 as well as MuRF2.
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